Business Context and Reporting Period
This Form 8-K, dated May 24, 2021, reports the results of the annual meeting of stockholders for NRX Pharmaceuticals, Inc. (formerly Big Rock Partners Acquisition Corp., or "BRPA"). The meeting was held to approve the business combination with NeuroRx, Inc. ("NeuroRx") pursuant to a Merger Agreement dated December 13, 2020. The filing confirms the completion of the transactions and the subsequent name change to NRX Pharmaceuticals, Inc.
Key Financial Metrics
This filing is a current report regarding corporate governance and transaction approval; it does not contain audited financial statements, revenue, profit, cash flow, or debt metrics for the company. The filing text does not provide a clear value for financial performance indicators.
Material Changes and Voting Results
Stockholders representing 2,135,500 shares (a quorum) voted unanimously (2,135,500 For, 0 Against, 0 Abstain) to approve the following material changes:
- Business Combination: Approval of the merger between BRPA and NeuroRx, Inc.
- Corporate Name: Change from "Big Rock Partners Acquisition Corp." to "NRX Pharmaceuticals, Inc."
- Capital Structure: Increase in authorized common stock from 100,000,000 to 500,000,000 shares and preferred stock from 1,000,000 to 50,000,000 shares.
- Charter and Bylaw Amendments: Adoption of new governance provisions, including supermajority voting requirements for certain charter amendments and removal of SPAC-specific provisions.
- Stock Issuance: Approval to issue 75,200,000 shares to NeuroRx securityholders and 1,000,000 shares to PIPE investors.
- Board Composition: Election of six directors: Chaim Hurvitz, Daniel Troy, Sherry Glied, Aaron Gorovitz, Patrick Flynn, and Jonathan Javitt.
- Equity Plan: Approval of the 2021 Long-Term Incentive Equity Plan.
Outlook, Risks, and Unusual Items
The filing confirms the completion of the merger transactions as announced in a press release dated May 25, 2021 (Exhibit 99.1). No specific forward-looking guidance, risk factors, or contingencies are detailed within the text of this specific 8-K filing, other than the standard disclosure that the press release information is not deemed "filed" under the Exchange Act.
Investor Verification Checklist
- Verify the final post-merger share count and dilution impact based on the issuance of 75,200,000 shares to NeuroRx and 1,000,000 shares to PIPE investors.
- Review the attached press release (Exhibit 99.1) for specific details on the transaction closing and immediate financial position.
- Confirm the effective date of the new charter and bylaws following the consummation of the business combination.
- Check the composition and expertise of the newly elected board of directors.
- Monitor subsequent filings for the first set of financial statements reflecting the combined entity.